Targeting Trends

by Carl Noe, M.D., Anesthesiology & Pain Management, UT Southwestern Medical Center, Dallas, TX; and Eugene McDermott Center for Pain Management, Dallas, Texas Dr. Noe is the Principal Investigator in the ongoing trial of SP-SAP Intrathecal SP-SAP (Substance P attached to the ribosome-inactivating protein, saporin) has been studied in a Phase 1 clinical trial of

by Masahiro Sato1 (Ph. D.) and Satoshi Watanabe2 (Ph. D.) 1Section of Gene Expression Regulation, Frontier Science Research Center, Kagoshima University, Kagoshima 890-8544, Japan: 2Animal Genome Research Unit, Division of Animal Science, National Institute of Agrobiological Sciences, Ibaraki 305-8602, Japan Isolation of stable transfectants is one of the important steps for exploring biological functions of

Congratulations to Dr. Kucinski as this year’s winner of the SfN Poster of the Year Award for the most interesting work presented using ATS products. You can read a summary of this work from Dr. Sarter’s lab in the cover article in this issue of Targeting Trends. Here is a small sample of the comments

by Aaron Kucinski (Collaborators at University Michigan, Ann Arbor: K. Phillips, R. Albin, M. Sarter) In addition to the primary disease-defining symptoms that result from extensive loss of nigrostriatal dopaminergic neurons, approximately half of patients with Parkinson’s Disease (PD) suffer from postural instability, impairments in gait control and a propensity for falls. These symptoms have